modelStreptozocin

Diagram of Streptozocin

Extends from Pharmacolibrary.Drugs.ATC.L.L01AD04.

Information

name:Streptozocin
ATC code:L01AD04
route:intravenous
compartments:2
dosage:1000mg
volume of distribution:26L
clearance:240ml/min
other parameters in model implementation

Streptozocin is an antineoplastic agent belonging to the nitrosourea class. It is specifically used for the treatment of pancreatic islet cell carcinoma (pancreatic neuroendocrine tumors). Streptozocin is an alkylating agent approved for clinical use but mainly reserved for rare tumors due to its toxicity profile.

Pharmacokinetics

Pharmacokinetic parameters observed in adult patients with metastatic islet cell carcinoma receiving intravenous infusion.

References

  1. Kim, YC, et al., & Lee, MG (2008). Pharmacokinetics of phenytoin and its metabolite, 4'-HPPH, after intravenous and oral administration of phenytoin to diabetic rats induced by alloxan or streptozotocin. Biopharmaceutics & drug disposition 29(1) 51–61. DOI:10.1002/bdd.591 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18022993

  2. Engler, FA, et al., & Balthasar, JP (2014). Investigation of the influence of nephropathy on monoclonal antibody disposition: a pharmacokinetic study in a mouse model of diabetic nephropathy. Pharmaceutical research 31(5) 1185–1193. DOI:10.1007/s11095-013-1241-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/24203494

  3. Chen, T, et al., & Mager, DE (2013). Population pharmacodynamic modeling of exenatide after 2-week treatment in STZ/NA diabetic rats. Journal of pharmaceutical sciences 102(10) 3844–3851. DOI:10.1002/jps.23682 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23897494

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)